摘要
We report the case of a 4- year-old boy receiving sodium valproate (VPA) therapy since 2 years who suddenly developed clinically relevant thrombocytopenia and signs of hepatotoxicity. Reduction of VPA dosage led to clinical and laboratory improvement, while discontinuation of therapy was not necessary. The current practice of managing VPA-induced side effects is discussed in view of current recommendations from the literature.
We report the case of a 4- year-old boy receiving sodium valproate (VPA) therapy since 2 years who suddenly developed clinically relevant thrombocytopenia and signs of hepatotoxicity. Reduction of VPA dosage led to clinical and laboratory improvement, while discontinuation of therapy was not necessary. The current practice of managing VPA-induced side effects is discussed in view of current recommendations from the literature.
